Physician profile
Jonathan Tobis
NPI 1811917073
$76,768.82
in general payments reported to CMS, 2019-2025
11 companies · $354 in 2025
The $354 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2021: $1,046 · 2022: $26K · 2023: $8,693 · 2024: $23K · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Travel and Lodging: $2,798 · Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,470.00 |
| Travel and Lodging | $2,797.89 |
| Food and Beverage | $1,935.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $74,119.55 | 2019-2024 | Gore Cardioform Septal Occluder, Gore Cardioform Asd Occluder |
| Abbott Laboratories | $1,222.07 | 2021-2025 | Dragonfly Opstar, Optis, Pressurewire |
| Penumbra, INC. | $383.54 | 2022 | |
| Edwards Lifesciences Corporation | $183.41 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Shockwave Medical, INC | $173.28 | 2021 | |
| Boston Scientific Corporation | $165.55 | 2025 | Emerge Push |
| Abiomed | $145.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.58 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $120.54 | 2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $120.09 | 2024 | Imfinzi |
| Cook Medical LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Tobis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.